There is one clinical trial.
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
Description: Number of participants that require ECMO Number of participants that cannot be extubated within 10 days or A downward change in Oxygenation Index by >15% from baseline
Measure: Reduction in Respiratory Failure Time: 10 daysDescription: Number of participants that require ECMO Number of participants requiring inotropic therapy Number of participants that require mechanical circulatory support A change in Cardiac Troponin >20% from baseline or A change in BNP >15% from baseline
Measure: Reduction in Cardiac/Circulatory Failure Time: 10 daysDescription: Number of participants that demonstrate a change in FiO2 by 50% or more.
Measure: Improvement in Oxygenation Time: 10 daysDescription: Number of participants with a reduction in the time to extubation Number of participants with a reduction in ICU days Number of participants with a reduction in hospital days
Measure: Improved Clinical Outcomes Time: 28 days